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EPO does not promote interaction 
between the erythropoietin and 
beta-common receptors
Karen S. Cheung Tung Shing1,2, Sophie E. Broughton1,2, Tracy L. Nero1,2, Kevin Gillinder3, 
Melissa D. Ilsley4, Hayley Ramshaw5, Angel F. Lopez5, Michael D. W. Griffin2, 
Michael W. Parker1,2, Andrew C. Perkins3 & Urmi Dhagat  1,2
A direct interaction between the erythropoietin (EPOR) and the beta-common (βc) receptors to form 
an Innate Repair Receptor (IRR) is controversial. On one hand, studies have shown a functional link 
between EPOR and βc receptor in tissue protection while others have shown no involvement of the βc 
receptor in tissue repair. To date there is no biophysical evidence to confirm a direct association of the 
two receptors either in vitro or in vivo. We investigated the existence of an interaction between the 
extracellular regions of EPOR and the βc receptor in silico and in vitro (either in the presence or absence 
of EPO or EPO-derived peptide ARA290). Although a possible interaction between EPOR and βc was 
suggested by our computational and genomic studies, our in vitro biophysical analysis demonstrates 
that the extracellular regions of the two receptors do not specifically associate. We also explored the 
involvement of the βc receptor gene (Csf2rb) under anaemic stress conditions and found no requirement 
for the βc receptor in mice. In light of these studies, we conclude that the extracellular regions of the 
EPOR and the βc receptor do not directly interact and that the IRR is not involved in anaemic stress.
Under physiological conditions, erythropoietin (EPO) is continually produced by the kidney to regulate erythro-
poiesis1,2. EPO generates erythrocytes by binding to a homodimer of the erythropoietin receptor (EPOR) on par-
ent erythrocyte cells. The binding affinity of EPO to the EPOR homodimer expressed on erythroblasts has been 
reported to be ~100–200 pmol/L3,4. The EPOR is a single transmembrane receptor comprised of an N-terminal 
extracellular domain containing an EPO binding region, followed by the transmembrane domain (thought to be 
largely α-helical) and a C-terminal intracellular region (Fig. 1). EPO binds to EPOR on the cell surface, resulting 
in re-orientation and activation of the EPOR receptor5,6 and JAK2 phosphorylation of tyrosine (pY) residues in 
the intracellular region of EPOR. The phospho-tyrosine residues act as docking sites for signalling partners such 
as STAT5, which are then phosphorylated to mediate pathways elicited by EPOR7–10, culminating in the prolifer-
ation, survival and differentiation of erythrocytes.
Interestingly, EPO has also been shown to have an effect on non-haematopoietic cells such as endothelial cells, 
heart, kidney and cells in the central nervous system albeit at significantly higher concentrations (1–2 nmol/L) 
than that needed for haematopoiesis2. The substantial difference in affinity for the EPOR homodimers expressed 
by erythrocyte precursors and receptors on non-haematopoietic cells suggested that a different receptor may be 
involved in mediating the non-haematopoietic effects of EPO2. Based on immunoprecipitation studies, Brines 
and co-workers proposed that the non-haematopoietic effects of EPO were mediated by a heterodimer of EPOR 
and the beta common (βc) receptor11–13, which was referred to as the “Innate Repair Receptor” (IRR)11,13–17. The 
βc receptor also belongs to the type I cytokine receptor superfamily and is the main signalling subunit shared by 
granulocyte macrophage colony stimulating factor (GM-CSF, Fig. 1a,b), interleukin (IL)-3 and IL-5. It has been 
proposed that EPOR and the βc receptor are typically localised within the intracellular compartment in quiescent 
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Figure 1. Signalling pathways triggered by EPOR homodimers, the putative EPOR:βc IRR heterodimer and the 
GM-CSF:GM-CSFRα:βc dodecamer complex. (a) EPOR (green) can form homodimers (left) or heterodimers 
(middle) with the βc receptor (shades of blue). Upon stimulation with EPO (grey), the EPOR homodimer 
promotes erythroid cell differentiation and survival. The EPOR:βc IRR heterodimer has been hypothesised 
to promote tissue protection and healing in non-haematopoietic cells and may play a role in anaemic stress. 
The GM-CSF ternary complex (GM-CSF + GM-CSFRα + βc; shades of pink, orange and blue, respectively) 
forms higher order signalling complexes (e.g. βc dodecamer complex) and contributes to blood cell survival, 
proliferation and differentiation. The different sites of interaction in the GM-CSF ternary complex (labelled as 
βc dodecamer complex) are indicated in red. The cell membrane location is indicated by the horizontal blue 
line. (b) The structure of the GM-CSF:GM-CSFRα:βc hexamer complex (prepared using PDB ID: 4NKQ and 
4RS1)33 displayed in cartoon format. GM-CSF, GM-CSFRα and βc are coloured pink, orange and shades of blue 
respectively. For the docking studies, the βc receptor was truncated to the membrane proximal D1/D4 domains 
only (as indicated by *) due to the size restriction of RosettaDock. The membrane proximal D1/D4 domains 
are the domains in contact with the cytokine and they participate in the formation of Sites 2 and 3. (c) The 
structure of EPO:EPOR homodimer complex displayed in cartoon format (PDB ID: 1EER)35. The location of 
the EPO:EPOR interaction surfaces, Sites 1 and 2, are indicated. EPO is coloured grey and EPOR green.
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cells, but under stress conditions, such as hypoxia or inflammation, these receptors are rapidly mobilised to the 
cell surface2,18,19. Binding of EPO to the IRR is thought to trigger distinct signalling pathways initially mediated 
by JAK2 phosphorylation2,12, ultimately decreasing apoptosis and inflammation and promoting tissue repair2,20,21 
(Fig. 1a).
Brines and co-workers13 showed that βc receptor knockout mice had less motor recovery compared to wild 
type mice upon EPO administration, suggesting involvement of the βc receptor in tissue repair. Furthermore, 
cardiomyocytes isolated from βc knockout mice were found to have higher rates of apoptosis compared to those 
extracted from the wild type mice after EPO treatment13. Blake and co-workers12 demonstrated that BAF-B03 
cells co-expressing the EPOR and βc receptor could induce downstream JAK2 phosphorylation upon EPO stim-
ulation. Other studies have demonstrated that the βc receptor is involved in the induction of nitric oxide upon 
EPO stimulation16,22,23. Several groups have thereafter studied EPO derivatives such as ARA290, a peptide derived 
from helix B of EPO24, that could potentially activate the proposed IRR but not the EPOR homodimer. These 
derivatives would help in tissue repair and protection in pathological conditions without affecting physiological 
haematopoiesis24–27, as has been demonstrated by several studies demonstrating the protective effects of these 
EPO derivatives28–30.
However, there has been no evidence of a direct interaction between the βc receptor and EPOR to date. On 
the contrary, studies of steady state erythropoiesis and erythroid colony formation in Csf2rb knockout mice 
(Csf2rb−/−; Csf2rb is the gene coding for the equivalent βc receptor in mice) have shown no involvement of the 
EPOR:βc IRR heteroreceptor in steady state haematopoiesis, as there was no difference in baseline haematopoiesis 
in βc knockout mice compared to wild type31. The growth of bone marrow cell cultures isolated from βc knockout 
and wild type mice were also similar after EPO treatment, again supporting no involvement of the βc receptor 
in steady state erythropoiesis31. Furthermore, Kanellakis and co-workers32 demonstrated that darbepoietin, a 
derivative of EPO, acted as a cardioprotective agent independently of IRR in mice when cardiac infarction was 
induced. The level of inflammation, fibrosis and apoptosis was reduced to a similar extent in βc knockout and wild 
type mice after darbepoietin administration, indicating that the βc receptor was not involved in tissue protection 
and repair32. These studies are in conflict with the proposed involvement of the EPOR:βc IRR heteroreceptor in 
mediating tissue protective effects in response to EPO and its derivatives.
To date, many studies have investigated the tissue protective effects of EPO and its derivatives in different 
models13,25,28–30, however no direct interaction between the EPOR and βc receptor has been reported. The crystal 
structures of the extracellular domains of EPOR in complex with EPO and the GM-CSF:GM-CSFRα:βc ternary 
complex have been determined (GM-CSFRα is the cytokine specific receptor α-subunit which interacts with the 
shared receptor subunit βc, Fig. 1b,c). These structures have provided molecular insight into the mechanism of 
assembly and activation of the EPO and GM-CSF receptor systems5,33–35. Previous studies have demonstrated 
that the extracellular regions of the type I cytokine receptors play a significant role in homo and heteroreceptor 
assembly in vitro36. Since the molecular determinants driving the formation of the IRR heteroreceptor have not 
been clearly established, we decided to investigate whether the extracellular regions of the two receptors could 
associate with each other in vitro, in the presence and absence of EPO or the helix B peptide, ARA290. We 
investigated the possibility of an association between EPOR and the βc receptor through in silico studies, in 
vitro biophysical assays and an in vivo mouse model (under anaemic stress). In the absence of EPO, our in silico 
docking experiments suggested that the extracellular membrane proximal domains of EPOR and the βc receptor 
can directly interact to produce a pre-formed IRR heteroreceptor. However, the docking studies also suggested 
that the extracellular membrane proximal domains of these two receptors cannot directly interact in the presence 
of EPO. Rather, the modelled EPO:EPOR:βc complex is structurally similar to that observed in the EPO:EPOR 
homodimer crystal structures (PDB IDs: 1CN4 and 1EER)35. Thus, our modelling data suggests that the IRR 
heteroreceptor is structurally possible. We next established that EPO induced rapid upregulation of the Csf2rb 
gene in an erythroid cell line via pSTAT5 binding to the promoter. In contrast, there was no involvement of 
the βc receptor in recovery from anaemic stress in an in vivo mouse model. Moreover, we could not detect any 
physical interaction between the extracellular domains of the two receptors in vitro using a variety of biophysical 
techniques. This is the first study to clearly demonstrate that the two receptors do not directly interact via their 
extracellular domains in vitro and do not functionally interact in vivo in response to anaemic stress.
Results and Discussion
The βc gene is a direct and immediate transcriptional target of pSTAT5. We recently undertook 
a study to find direct targets of pSTAT5 following stimulation of murine erythroid cells (J2E cells) by EPO37. We 
found rapid induction of Csf2rb (Fig. 2a) and Csf2rb2 (not shown), and strong EPO-induced binding of pSTAT5 
to the Csf2rb promoter. The critical erythroid transcription factor, GATA1, also binds the Csf2rb promoter in 
erythroid cell lines (Fig. 2a). Genes encoding the well-established partners of the βc receptor were not expressed 
in J2E cells or induced by EPO; i.e. IL-3Rα, GM-CSFRα and IL-5Rα. We confirmed EPO induction of Csf2rb 
in an independent dynamic CAGE dataset38 (Fig. 2b), and up regulation of the βc receptor (CD131) at the cell 
surface in J2E cells 6 hr after EPO stimulation (Fig. 2c). Thus, we hypothesised that an EPO-induced (“stressed”) 
heterodimer between EPOR and the βc receptor (or IRR), might occur in erythroid cells and provide an alter-
native signal generation mechanism or amplified JAK2 signalling in erythroid progenitors after stress. Such an 
EPOR:βc IRR heteroreceptor has been suggested to mediate survival and repair signals in response to EPO in 
non-haematopoietic cells2,11–13,25,39, but there have never been any direct biophysical or structural studies to con-
firm or refute such a possibility.
In silico docking studies suggest that the formation of an IRR heteroreceptor is plausi-
ble. Using existing crystal structures of the EPOR and βc receptor, we constructed models of the proposed 
EPOR:βc IRR heteroreceptor to investigate how the extracellular regions of these two receptors might interact. 
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We considered two possibilities, one where the IRR heteroreceptor would pre-form in the absence of EPO (i.e. 
resulting in the formation of Site 3, Fig. 1) and a second where EPO would mediate the heterodimerisation 
between EPOR and the βc receptor (i.e. with possible formation of Sites 1–3, Fig. 1). Due to the homodimeric 
nature of the βc receptor, the modelling presented here could involve both D4 regions of the βc homodimer (as 
illustrated in Fig. 1a,b).
In the absence of EPO, blind rigid body docking failed to produce an IRR heteroreceptor model where the 
membrane proximal domains of EPOR and the βc receptor (D2 of the EPOR and D4 of βc) were in contact 
forming the Site 3 interface. In a parallel approach, we constrained the D2 domain of EPOR and the D4 domain 
of βc to be membrane proximal throughout the docking process, facilitating the formation of Site 3 (i.e. biased 
docking using RosettaDock)40–42. For each EPOR crystal structure chain used in the biased docking (i.e. PDB IDs: 
1CN4 A chain, 1ERN B chain and 1EER B chain), the top ten ranked IRR heteroreceptor models were retained 
for analysis. Hence thirty IRR heteroreceptor models in total were analysed and, for each EPOR crystal structure 
chain, the IRR heteroreceptor model with the largest Site 3 interface was selected as a representative (Models 2–4, 
Supplementary Fig. 1b–d). A summary of the Site 3 interactions for IRR Models 2–4 is given in Supplementary 
Tables S1 and S2.
In the presence of EPO, two different scenarios were investigated while modelling the IRR heteroreceptor. 
In the first scenario, EPO was assumed to bind to the EPOR:βc IRR heteroreceptor in a similar manner to that 
observed in the crystal structures of the EPO:EPOR complex (PDB IDs: 1CN4, 1EEN), i.e. EPO interacting at 
Sites 1 and 2, and no formation of Site 3 (Figs 1c and 3a). The top twenty ranked biased docking solutions were 
Figure 2. Csf2rb is a direct immediate transcriptional target of pSTAT5. (a) ChIP-seq and 4sU-RNA-seq in 
J2E erythroid cells following 30 min of EPO stimulation at the Csf2rb gene demonstrate direct immediate 
regulation by pSTAT5. Read density per million mapped reads (y-axis) for pSTAT5 (ochre), KLF1 (orange) 
and GATA1 (brown) ChIP-seq. Coloured bars above each track represent peak summits as called by MACS2. 
Read density profiles (y-axis) for 4sU-RNA-seq from J2E cells (blue) and J2E cells post EPO-induction (red) 
are displayed for both forward (+ve values) and reverse (−ve values) strands. A schematic of gene structure 
and alternative transcripts from RefSeq is shown in black with scale bar. (b) CAGE tag counts expressed as 
relative log expression (RLE) over the indicated pSTAT5-occupied promoter (green bar in panel A) from 0 to 
24 hr post EPO stimulation. (c) FACS plot for CD131 (βc receptor) expression on the surface of J2E cells in the 
absence (grey) and 6 hr post (purple) stimulation with EPO (5 U/mL). One representative plot of 3 independent 
experiments is shown.
www.nature.com/scientificreports/
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analysed and the three EPO:EPOR:βc IRR models with the largest Site 1 and 2 interfaces were selected as repre-
sentative (Models 5–7, Fig. 3a, Supplementary Tables S3–S6). When EPO is bound to the EPOR:βc IRR heter-
oreceptor in this manner, the membrane proximal domains of the two receptors cannot physically interact at Site 
3 (Fig. 3a). In the second scenario, EPO was docked into either Site 1 of EPOR or Site 2 of the βc receptor in the 
pre-formed EPOR:βc IRR heteroreceptor Models 2–4 (i.e. Site 3 formed, Supplementary Fig. S1b–d). Docking 
EPO to EPOR Site 1 in Models 2 and 3 resulted in minor steric clashes between EPO and the βc receptor at Site 
2, whereas there were major Site 2 steric clashes in Model 4. The two crude EPO:EPOR:βc complexes were used 
as input to RosettaDock in an attempt to relieve the minor steric clashes between EPO and βc, however this was 
unsuccessful and in each case EPO was ejected from Site 2 (Models 8–9, Fig. 3b, Supplementary Tables S3–S6). 
When EPO helix A is docked into Site 2 of the βc receptor, in an analogous manner to the way in which GM-CSF 
interacts with βc at Site 2 (Fig. 1), EPO cannot physically fit into the groove formed by EPOR and βc while the Site 
3 interaction between EPOR and βc is maintained.
Based on our docking studies, and protein-protein interface analysis, it appears that the only feasible way 
EPO can interact with the EPOR:βc IRR heteroreceptor is via scenario one, i.e. formation of Sites 1 and 2, no Site 
3 (Models 5–7, Fig. 3a). This is structurally analogous to the EPO:EPOR complexes (PDB IDs: 1CN4, 1EEN), 
however since βc is a homodimer the IRR heteroreceptor may have the stoichiometry 2 EPO: 2 EPOR:1 βc 
Figure 3. Docking the extracellular domains of EPOR and the βc receptor in the presence of EPO. EPO:EPOR: 
βc IRR heteroreceptor models arising from the biased docking approach. EPO is shown as a grey cartoon, EPOR 
in green and βc (D1/D4) in blue. (a) Models 5–7 show EPO interacting with EPOR via Site 1 and βc (D1/D4 
only) via Site 2. When EPO is bound to Sites 1 and 2, the membrane proximal domains of EPOR (D2) and βc 
(D4) are too far apart to interact and form Site 3. These models are structurally analogous to the EPO:EPOR 
homodimer complex. (b) To construct Models 8–9, EPO was docked to Site 1 of EPOR in the pre-formed 
heteroreceptor Models 2 and 3 (i.e. Site 3 has already formed, Supplementary Fig. S1b,c). When the EPOR: 
βc interaction at Site 3 is maintained, EPO is physically unable to interact at Site 2. (c) The βc receptor is a 
homodimer (Fig. 1b) and therefore EPO and/or EPOR (model 5 used as representative) could interact at one or 
both ends of the βc receptor homodimer.
www.nature.com/scientificreports/
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homodimer (Fig. 3c). Although our modelling studies suggest that the extracellular regions of EPOR and the βc 
receptor could interact in the absence of EPO (i.e. formation of Site 3), the two receptors would be required to 
undergo structural rearrangement to enable the binding of EPO (i.e. formation of Sites 1 and 2) and subsequent 
receptor activation. In light of these results, we investigated the possibility of an interaction between the extra-
cellular domains of EPOR and the βc receptor in the absence, and presence, of EPO or the ARA290 peptide in 
vitro, and built up a model that would aid us in understanding the mechanism of formation of the IRR and the 
association of EPO to the IRR.
The extracellular regions of EPOR and the βc receptor do not associate in absence of EPO. We 
initially carried out binding experiments using commercially acquired EPOR (Sino Biological, China) and our 
in-house purified βc receptor. The commercially available EPOR protein demonstrated clear binding to the βc 
receptor in microscale thermophoresis (MST) and surface plasmon resonance (SPR) assays (Supplementary 
Fig. S2a,b), but not in analytical size exclusion chromatography (SEC) and in pull down assays. This prompted us 
to investigate the quality of the commercially acquired protein sample using analytical ultracentrifugation (AUC), 
which demonstrated that the commercially acquired protein was aggregated and thus unsuitable for our studies. 
Hence, an in-house EPOR protein was purified using established protocols43 and verified to be appropriate for 
carrying out binding studies (see Supplementary Fig. S2c).
Several studies have implicated the association of EPOR with the βc receptor to form an IRR heteroreceptor in 
response to high levels of EPO2,11,13–18, but there is no published biophysical evidence of their interaction in vitro. 
Thus, the in-house purified EPOR and βc receptor were used to investigate whether the extracellular domains 
of these two receptors interact in the presence or absence of EPO. The identity of the proteins was confirmed by 
visualisation in anti-His Western blotting and by tryptic digest mass spectrometry analysis. Circular dichroism 
indicated proper folding of EPOR (Supplementary Fig. S3), predicting the protein to consist of 2% α-helices, 
50% β-strands, 8% turns and 37% disordered, which was consistent with the DSSP secondary structure analy-
sis44 of the EPOR homodimer structure (PDB ID: 1ERN). Analysis of the βc receptor indicated that it contained 
11% α-helices, 35% β-strands, 24% turns and 31% disordered, which was consistent with the DSSP secondary 
structure analysis44 of the βc homodimer structure (PDB ID: 2GYS)45. The proper folding of the proteins has been 
tested in positive control binding assays (see below) to ensure the functionality of the proteins.
Initially, we looked for evidence of the formation of the EPOR:βc heterodimer in solution using analytical SEC 
and pull-down assays. Previous SEC studies have successfully shown the formation of higher molecular weight 
complexes between GM-CSF, GM-CSFRα and βc, thereby demonstrating that high affinity complexes involving 
the βc receptor can be detected using this biophysical technique34. For our analytical SEC studies, EPOR and the 
βc receptor were first injected separately and then together (in molar ratios 1:1 and 1:3), after incubation for one 
hr on ice. The EPOR:βc mixture was analysed in two different running buffers at different pH values (pH 4.5 and 
pH 7), and with different incubation times (1–4 hr on ice) but in all cases, two separate peaks were obtained in the 
elution profiles when the EPOR + βc mixtures were injected (see Supplementary Fig. S4). One peak corresponded 
to the βc receptor at ~1.8 mL and the second peak to EPOR at ~2.3 mL (Fig. 4a). The fractions collected from the 
SEC were visualised on SDS-PAGE gels and analysed by mass spectrometry to confirm the results. The absence of 
an elution volume peak <1.8 mL indicates that there was no higher molecular weight complex formed between 
EPOR and the βc receptor.
In a different approach, a pull down assay was conducted, where the resin was first incubated with EPOR-His, 
washed thoroughly with buffer and then incubated with the βc receptor. The resin was then washed and the 
bound proteins were eluted. EPOR-His was eluted from the resin (band at 32 kDa), but there was no band on the 
gel corresponding to the βc receptor (50 kDa), indicating that βc did not bind to EPOR-His (Fig. 4b). Although 
there was a faint band at the βc receptor molecular weight in the elution, this same faint band was also observed in 
the control experiment, indicating some residual non-specific binding of βc to the resin. Thus, the analytical SEC 
and pull down assays suggest that either the extracellular domains of EPOR and the βc receptor do not interact 
with each other or that the interaction may be too weak to be detected by these methods. Therefore, more sensi-
tive techniques such as SPR and MST were pursued to investigate the possibility of IRR formation.
For the MST experiments, purified EPOR (30 nM) was labelled and titrated against different concentrations 
of unlabelled βc receptor (1.5–50000 nM) The mixture was excited with different infra-red laser powers (20%, 
40%, 60%) and the thermophoretic experiment was repeated several times using different glass capillaries (stand-
ard, hydrophobic, hydrophilic), but none of these experiments exhibited a conclusive binding event (Fig. 5a). 
However, when labelled EPOR was titrated against unlabelled EPOR (0.05–1700 nM) as a positive control, a 
well-defined binding curve corresponding to the formation of an EPOR homodimer was observed (Fig. 5b). This 
is the first report of an affinity for the extracellular domains of the EPOR homodimer in vitro in the absence of 
EPO (Kd of 166 ± 16 nM), which was also observed in the apo EPOR homodimer structure5. The data are consist-
ent with previous studies, which showed that the extracellular domains of EPOR were sufficient for the formation 
of the homodimer in cell lines expressing truncated mutants of EPOR lacking the intracellular domain46.
In parallel, we performed SPR experiments where biotinylated EPOR was immobilised on a CM5 chip 
through an anti-biotin antibody (Fig. 5c,d). The surface showed binding of EPO as a positive control, but no 
binding to carbonic anhydrase as a negative control, validating the chip surface strategy (Fig. 5d). The βc receptor 
(0–32 μM) was injected over the chip surface, but no binding was observed (Fig. 5c). The experiment was repeated 
several times using different buffers, however there was no evidence of βc binding. We also tested binding of dif-
ferent concentrations of EPOR (0–500 nM) to biotinylated βc receptor immobilised on the chip surface but again 
no binding was observed (Fig. 5e). As a positive control, we demonstrated binding of the IL-3 binary complex 
(IL-3 + IL-3Rα) to the βc receptor confirming that the membrane proximal domains (D4) of the βc homodimer 
were available for interaction and that the βc surface was active (Fig. 5f). Both the MST and SPR experiments 
indicate that extracellular regions of EPOR and the βc receptor do not associate to form the IRR heteroreceptor.
www.nature.com/scientificreports/
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EPO does not bring the extracellular domains of EPOR and the βc receptor together. Analytical 
ultracentrifugation (AUC) studies were undertaken to investigate whether EPO played a role in bringing the two 
receptors together. AUC is an in-solution technique with no modification of the protein, and thus mitigates the 
effects of protein modification that occurs to some extent in MST (dye labelling) and SPR (biotinylation and 
immobilisation of protein) experiments. We found EPOR and βc do not interact in the AUC system. We then 
included EPO in our experiments, to determine whether the ligand was required to mediate the interaction 
between EPOR and the βc receptor. Sedimentation coefficients of 2.1S, 2.3S and 4.4S were determined for the 
EPOR monomer, EPO and βc homodimer, respectively (Fig. 6a). Different combinations of the proteins were 
then evaluated for possible interaction. We demonstrated binding of EPO to EPOR, with a sedimentation coeffi-
cient of 3.5S (Fig. 6b). However, we could not identify any interaction between EPOR and the βc receptor in the 
absence (Fig. 6c) or presence (Fig. 6d) of EPO. When all three proteins were present, the signal for EPO and the 
EPO + EPOR complex was relatively low. As a result, the peaks corresponding to EPO and the EPO + EPOR com-
plex were apparent as a single peak with average sedimentation coefficient of approximately 2.7S, and significant 
broadening of this peak was observed at the lower βc concentrations. Overall, there was no significant change 
in the βc receptor peaks in the mixtures assayed and no new peak at a higher sedimentation coefficient was 
observed, indicating that no higher order complex formation between EPOR and the βc receptor was detectable 
over these concentration ranges. Thus, the AUC data further confirmed that the extracellular domains of EPOR 
and the βc receptor do not specifically interact in vitro, in the absence or presence of EPO.
Figure 4. Analytical SEC and pull down assays could not detect binding between the purified EPOR and βc 
receptor proteins. (a) Overlay of the 280 nm UV absorbance spectra for EPOR, the βc receptor and EPOR + βc 
injected into the SEC column. (b) Pull down assays were carried out with EPOR-His incubated with His-Tag 
resin and then with the βc receptor after washing. (c) A control experiment with initial incubation with buffer 
instead of EPOR-His was also carried out. In both panels (b) and (c), samples loaded on the coomassie stained 
gels were 1: Supernatant after incubation with resin, 2–6: Washes 1–5 after initial incubation with resin, 7: 
Supernatant after incubation with βc, 8–12: Washes 6–10 after incubation with βc, 13: Resin after washing, 
14: Molecular weight marker. EPOR-His and the βc receptor are indicated by the blue and black arrows, 
respectively. Shown are representative data from a single experiment. N = 3 separate experiments were carried 
out.
www.nature.com/scientificreports/
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ARA290 cannot mediate an interaction between the extracellular domains of EPOR and the 
βc receptor. Lastly, we tested whether the peptide ARA290 could bring the extracellular domains of EPOR 
and the βc receptor together28. ARA290 has been reported to preferentially bind to the proposed IRR heter-
oreceptor and not to the EPOR homodimer24,26–28,47. We first carried out pull down assays where EPOR-His 
was immobilised on resin before being incubated with ARA290 or βc + ARA290. The components bound to 
the resin were eluted and visualised on an SDS-PAGE gel. No binding of EPOR to ARA290 or βc + ARA290 was 
Figure 5. MST and SPR data suggest that the purified extracellular domains of EPOR and the βc receptor 
do not associate. (a) The purified EPOR (30 nM) was labelled and titrated with a range of βc receptor 
(1.5–50000 nM) concentrations in MST assays with laser powers of 60%. No binding curve was observed 
between EPOR and the βc receptor. (b) A control experiment with a concentration range of unlabelled EPOR 
(0.05–1700 nM) titrated against the labelled EPOR (30 nM) was carried out at 60% laser power and indicated 
formation of the EPOR homodimer with a Kd of 166 ± 16 nM (mean ± SEM). (c) No binding was observed 
when different concentrations of the βc receptor were injected onto a surface of immobilised EPOR in SPR 
assays. (d) The integrity of the chip surface in the SPR assays was validated by injecting EPO as a positive 
control and carbonic anhydrase as a negative control. (e) Likewise, no binding was observed when different 
concentrations of EPOR were injected onto a surface of immobilised βc receptor in SPR experiments. (f) The 
integrity of the chip surface of immobilised βc receptor in SPR was validated by injecting the IL-3 binary 
complex (IL-3 + IL-3Rα) as a positive control. Shown are representative data from a single SPR experiment. 
Each MST and SPR experiment was conducted in duplicate, with N = 3 separate experiments.
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observed (Fig. 7a), although some non-specific binding of the βc receptor to the resin was observed, as confirmed 
by the control experiment (i.e. absence of any EPOR-His on the resin). Mass spectrometry confirmed that the 
ARA290 peptide was not pulled down with EPOR. The reverse experiment was also performed, where βc-His 
was immobilised on the resin and incubated with EPOR or EPOR + ARA290. Again, no binding of the peptide 
or EPOR + ARA290 was observed as determined by SDS-PAGE gel and mass spectrometry. We further explored 
the possibility of the ARA290 peptide binding to EPOR and/or the βc receptor in MST assays. Labelled EPOR was 
incubated with ARA290 and a range of βc concentrations (1–50000 nM) were titrated. The MST results confirmed 
that the extracellular domains of EPOR and βc did not interact, even in the presence of ARA290 (Fig. 7b). SPR 
was also carried out to test whether the βc receptor could bind to immobilised EPOR in the presence of ARA290 
(2:1 ratio of ARA290:βc) injected. The βc receptor (0–32 μM) was injected in the presence of ARA290 (0-64 μM) 
but no binding was observed to the immobilised EPOR (Fig. 7c), consistent with the pull-down and MST assays 
results.
Recovery from anaemic stress is not compromised in the absence of Csf2rb. There are conflicting 
reports about the role of the βc receptor in mediating signals in erythroid progenitor cells in response to EPO. 
One group has reported that the forced overexpression of the βc receptor in BaF3/EPOR cells leads to increased 
sensitivity to EPO11. However, there are no reported changes in red blood cell numbers, size or haematocrit in 
Csf2rb knockout mice31. These analyses were undertaken without any stress placed on red blood cell production 
rates. Since the majority of studies have shown that the βc receptor only associates with EPOR under stress con-
ditions, and not in steady state haematopoiesis, we investigated the possibility of the formation of the IRR heter-
oreceptor in response to stress in erythroid cells. Moreover, direct upregulation of Csf2rb in J2E cells (equivalent 
to BFU-e) after exposure to EPO (Fig. 2), suggested a possible role for the βc receptor in recovery from the stress 
of phenylhydrazine-induced haemolysis in Csf2rb knockout mice (see Materials and Methods). However, there 
were no significant differences in the recovery of red blood cell count (Fig. 8a), other red blood cell parameters 
(not shown) or haematocrit (Fig. 8b) in Csf2rb−/− mice compared to wild type C57BL/6 mice after a single dose of 
phenylhydrazine (60 mg/kg). Furthermore, there was no difference in recovery after a second higher dose of phe-
nylhydrazine (90 mg/kg) given on day 7 (D7, Fig. 8a) and the spleen weights were similar between Csf2rb−/− mice 
and wild type mice at D14 (Fig. 8c). Therefore, we conclude that the βc receptor plays no role in EPO signalling in 
vivo at baseline or in response to anaemic stress.
Figure 6. AUC studies indicate no association between the EPOR and βc receptor extracellular domains. (a) 
The EPOR, EPO and βc receptor proteins were characterised by AUC studies with sedimentation coefficients 
of 2.1 S, 2.3 S and 4.4 S, respectively. (b) EPO bound to the EPOR in the AUC studies, forming a complex with a 
sedimentation coefficient of approximately 3.5S. (c) Binding of the βc receptor to EPOR in the absence of EPO 
was not detected. (d) Binding of the βc receptor to EPOR in the presence of EPO was not detected. Shown are 
representative data from a single experiment.
www.nature.com/scientificreports/
1 0SCientifiC REPORTS | (2018) 8:12457 | DOI:10.1038/s41598-018-29865-x
Conclusions
Previous studies have suggested that an IRR formed by the heterodimerisation of EPOR and the βc receptor might 
mediate EPO-induced tissue healing and repair2,11,13–18, and that such a heterodimer might increase JAK-STAT 
signalling in response to EPO in blood cell lines11. Our in silico docking studies demonstrated that the forma-
tion of a heterodimeric complex between the extracellular domains of EPOR and the βc receptor was plausible. 
If the IRR heteroreceptor forms in the absence of EPO, subsequent ligand binding would cause the membrane 
Figure 7. EPOR and the βc receptor do not associate in the presence of the ARA290 peptide. (a) Pull down 
assays were carried out with either EPOR-His or βc-His immobilised on resin incubated with either the βc 
receptor or EPOR in the presence of ARA290 after washing. In a second experiment, the immobilised EPOR-
His or βc-His was incubated with the ARA290 peptide only. In control experiments, the resin was incubated 
with either untagged βc receptor or EPOR. Each experiment was repeated to validate pull-down data. (b) The 
effect of ARA290 upon EPOR and βc receptor association was also investigated using MST. Purified EPOR 
(30 nM) was labelled and incubated with ARA290 (60 nM) before being titrated with a range of βc receptor 
concentrations (1.5–50000 nM) at laser powers of 20%, 40% and 60%. Shown is representative data from a single 
experiment. Each experiment was carried out as three separate repeats (N = 3). (c) SPR studies with a mixture 
of βc (0–32 µM) and ARA390 (0–64 µM) injected over immobilised EPOR. Shown is representative data from a 
single experiment. Each experiment was carried out as three separate repeats (N = 3).
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proximal domains of the two receptors to move apart and there would be little or no interaction between the 
extracellular domains of these receptors (i.e. no Site 3 interface, Fig. 3a,c). The resulting EPO:EPOR:βc complex 
would therefore be structurally analogous to what is observed in the EPO:EPOR crystal structures. However, our 
multi-faceted biophysical studies using the extracellular domains of the two receptors showed that the proposed 
IRR heteroreceptor does not form in the absence or presence of EPO or the EPO-derived peptide, ARA290, under 
a broad range of in vitro conditions (pH 4.5–8, 50–500 mM NaCl, 4–25 °C, immobilised or in solution). It is pos-
sible that the transmembrane and/or intracellular regions of the two receptors might play a role in mediating an 
interaction between the EPOR and the βc receptor, as suggested by previous studies48,49. Blake and co-workers12 
also demonstrated that the W282R mutation in the intracellular domain of EPOR and deletion of the intracel-
lular box 1 of βc abrogated any downstream phosphorylation of JAK2 upon EPO treatment of BAF-B03 cells 
co-expressing both the EPOR and βc receptor.
Moreover, our haemolytic stress studies suggest that there is no functional interaction between intact 
EPOR and the βc receptor. Bohr and co-workers19 previously suggested that the IRR heteroreceptor is formed 
Figure 8. Normal recovery of Csf2rb knockout mice from anaemic stress. (a) Serial red blood cell count 
(RCC) in Csf2rb (red) and wild type (blue) after an initial (60 mg/kg) and second (90 mg/kg) injection of 
phenylhydrazine i.p. (b) Haematocrit (HCT) measurement in the same cohort. Values are mean ± SD of four 
mice; **p value < 0.01; *p value < 0.05 by student’s t test (c) Average spleen weight in the same cohort at D14 
(N = 4 in each group); error bars indicate ± SD.
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intracellularly and is externalised upon stress through membrane rafts in response to injury or a surge of EPO 
levels. The spatial and temporal coordination of stress and EPO surge were not investigated in this study and 
may be relevant factors that encourage IRR formation or externalisation. Another possibility is that there is no 
direct interaction between EPOR and the βc receptor to mediate healing and tissue protection or recovery from 
stress. Rather, the effects of EPO might be indirect through an intermediary agent, as previously suggested by 
Brines and co-workers13, who suggested that there might be other components to the EPOR:βc protein complex. 
This hypothesis is consistent with several studies that identified the presence, or upregulation, of the βc receptor 
together with EPOR during injury or stress induced in mouse models or cells11,13–17, but no evidence of a direct 
interaction between the two receptors has ever been reported. Although no direct interaction between the extra-
cellular regions of these two receptors was detected, it is possible that the transmembrane and/or intracellular 
regions of the EPOR and βc receptor may associate to form the IRR. There may well be a link between EPOR and 
the βc receptor in the mediation of tissue repair and protection under stress, but our present studies demonstrated 
that there was no direct interaction between the extracellular regions of these two receptors and that the IRR is 
not formed under anaemic stress.
Materials and Methods
ChIP-Seq and RNA-seq. ChIP-seq for pSTAT5 in murine erythroid cells and RNA-seq to find direct tar-
gets of JAK-STAT5 signalling were undertaken as recently reported37. The primary data from Gene Accession 
Omnibus under accession GSE94301 was uploaded into the UCSC Genome Browser for visualisation. The Zenbu 
Genome Browser was interrogated for dynamic CAGE data changes after EPO (epoetin alpha from Janssen-
Cilag) stimulation of the murine erythroid cell line, J2E38. For FACS, J2E cells were harvested 6 hr after ± EPO 
(5 U/mL), and stained for surface CD131 (βc receptor) using BD Biosciences PE-conjugated rat anti-mouse 
CD131 (Cat#559920).
In silico docking of EPOR to the βc receptor in the absence of EPO. Initial starting complexes of the 
membrane proximal domains of EPOR (D2, PDB IDs: 1ERN_A, 1EER_B, 1CN4_A) and the βc receptor (D1 of 
first monomer and D4 of second monomer, PDB ID: 4NKQ) were generated using using PyMOL v1.8.2.250 and 
SYBYL-X 2.1.151. To identify the individual EPOR and βc components used in each IRR heteroreceptor model 
the following nomenclature was used: [EPOR (PDB ID_chain]_[βc_GM-CSF; D1/D4 only]. The docking studies 
were performed using ClusPro2.052,53 for a blind rigid dock and RosettaDock Suite 3.4 software40–42 for a biased 
docking. The protein interfaces, surfaces and assemblies (PISA) service at the European Bioinformatics Institute54 
was used analyse the interacting interfaces and PredHS55 and KFC256 web servers were used to predict hot spot 
residues within the protein-protein interaction interface. All docking results were visualised in PyMOL. The 
details for feasible pre-formed EPOR:βc IRR heteroreceptor models are tabulated in Supplementary Tables S1 and 
S2 and the detailed methods are described in the Supplementary methods.
In silico docking of EPOR to the βc receptor in the presence of EPO. Two different scenarios were 
investigated for the docking studies in the presence of EPO. In the first scenario, it was assumed that EPO binds to 
the EPOR:βc IRR heteroreceptor in a similar manner to the way it interacts with the EPOR homodimer, i.e. with 
the formation of Sites 1 and 2 but not Site 3 (Fig. 1a,c). D4 of βc (D1/D4 only) from the GM-CSF ternary complex 
(PDB ID: 4NKQ)33 was aligned to D2 of EPOR in the two EPO:EPOR complexes (PDB IDs: 1EER and 1CN4)35. 
The EPO:EPOR (PDB IDs: 1EER A and B chains for EPO and EPOR, respectively and 1CN4 A and C chains 
for EPOR and EPO, respectively) and βc (D1/D4 only) components were merged together to form two starting 
EPO:EPOR:βc IRR complexes and these were used as input to RosettaDock; with the EPO:EPOR component 
defined as the receptor and βc (D1/D4 only) as the ligand.
In the second scenario, EPO was assumed to interact with the pre-formed IRR heteroreceptor in a similar 
manner to that of GM-CSF in the ternary complex, i.e. with the formation of Sites 1–3 (Fig. 1a,b). The models 
arising from the EPOR:βc docking in the absence of EPO were representative of this scenario and were used to 
dock EPO to EPOR Site 1 and, alternatively, to dock EPO to Site 2 of the βc receptor using RosettaDock. The 
protein interaction surfaces were analysed as described above. The details for putative EPO:EPOR:βc IRR heter-
oreceptor models are tabulated in Supplementary Tables S3–S6.
Purification of the extracellular region of EPOR. The pFastbac1 plasmid encoding the extracellular 
domains of the EPOR, with an N-terminal secretion tag (MKFLVNVALVFMVVYISYIYAD) and a C-terminal 
cleavable (TEV) 6xHis tag, was commercially cloned (BamHI and EcoRI restriction Sites, Bioneer, Australia). The 
in-house EPOR was expressed in High Five cells and purified using nickel affinity chromatography and SEC with 
the identity and quality of the protein verified (described in Supplementary data).
Purification of the extracellular region of the βc receptor. The pFastbac1 plasmid encoding the 
extracellular regions of the βc receptor with an N-terminal secretion tag (MKFLVNVALVFMVVYISYIYAD) 
and a C-terminal cleavable 6xHis tag was kindly donated by Dr. Timothy Hercus (Centre for Cancer Biology, SA 
Pathology and the University of South Australia, Adelaide, South Australia 5000, Australia). The βc receptor was 
expressed in attached Sf21 insect cells and purified by nickel affinity chromatography and SEC, with the identity 
and quality of protein verified (described in Supplementary data).
Analytical size exclusion chromatography (SEC). Analytical SEC was carried out using an S200 
increase GL 5/150 column (GE Healthcare) (50 mM phosphate, 150 mM NaCl pH 7 or 50 mM Na acetate, 150 mM 
NaCl pH 4.5) at room temperature. βc protein (50 μg or 150 μg) and EPOR protein (50 μg) were first each injected 
separately for characterisation. 50 μg each of EPOR and βc were then mixed together and incubated for one hr on 
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ice before injection on the SEC column. The different samples of EPOR:βc proteins were incubated and analysed. 
N = 3 separate experiments were carried out.
Pull down assays. The C-terminal 6xHis tags on the purified βc-His and EPOR-His were cleaved over-
night using TEV protease, with cleavage confirmed by performing an anti-His Western blot. EPOR-His (20 μg) or 
βc-His (20 μg) were first incubated with equilibrated complete His-tag purification resin (10 μg, Sigma Aldrich) 
for 1.5 hr, gentle rotation at 4 °C, followed by five washes with buffer (100 μL wash buffer, 50 mM phosphate, 
300 mM NaCl, 5 mM imidazole, pH 8). The resin with immobilised protein was then incubated with βc recep-
tor or EPOR (cleaved His tags) in the absence or presence of ARA290 (1:3 molar ratio of immobilised pro-
tein:ARA290) for 2 hr at room temperature and then again thoroughly washed. A small amount of resin was then 
boiled in reducing buffer to elute any bound proteins, which were resolved by SDS-PAGE. A control experiment 
where the resin was initially incubated with buffer instead of EPOR-His or βc-His was also carried out. Further 
experiments where the immobilised protein (EPOR-His or βc-His) was incubated with ARA290 were also con-
ducted. The SDS-PAGE gels were coomassie stained for visualisation. The ARA290 (pEQLERALNSS, pE = pyro-
glutamic acid) was commercially manufactured by Genscript as per details in28. Each experiment was repeated 
(N = 2) to validate pull-down results.
Microscale thermophoresis (MST) assays. The MST studies were carried out using a Nanotemper 
Monolith NT.115 instrument. The EPOR protein was labelled with dylight NHS Ester Dye 650 (Thermofisher 
Scientific) in a 1:1 molar ratio, with excess unbound dye removed by gravity flow SEC. 10 μL of the labelled EPOR 
at 30 nM was either directly titrated with 10 μL of the different concentrations of unlabelled protein (either βc 
receptor or EPOR) or was mixed with ARA290 in a 2:1 molar ratio of ARA290:EPOR and incubated for 1 hr on 
ice before being titrated with the unlabelled βc receptor and loaded into Monolith capillaries. All dilutions were 
made using the MST buffer (50 mM Tris, 10 mM MgCl2, 150 mM NaCl, 0.05% Tween 20, pH 7.5) provided in the 
Monolith capillaries kit (catalogue number MO-K002). The fluorescence of the capillary contents were analysed 
at 70% red light LED power to ensure standardisation of the labelled EPOR present in each capillary before each 
run. The contents of each capillary was then excited using an infra-red laser (20%, 40% and 60% laser power) for 
30 sec, allowing thermophoresis to occur, followed by 5 sec back diffusion (laser off). The normalised fluorescence 
(fluorescence after thermophoresis/initial fluorescence) was then recorded for each sample concentration and 
the data analysed using the Monolith NT Analysis software 1.5.41. A Sigmoidal 4 parameter logistic regression, 
with X as log (concentration), was used to fit the analysed data using GraphPad software57. Each experiment was 
conducted with N = 3 separate experiments. For the positive control experiment, i.e. unlabelled EPOR titrated 
against labelled EPOR, the 60% laser power data was used to calculate a Kd expressed as mean ± SEM.
Surface plasmon resonance (SPR) assays. SPR assays were performed on a Biacore T200 instru-
ment (GE Healthcare) at 25 °C, 30 μL/sec and in 50 mm phosphate, 150 mM NaCl, 0.05% Tween, pH 7 running 
buffer. Both the reference and active flow cells of the CM5 chip (GE Healthcare) were activated using NHS/
EDC and an anti-biotin antibody (B1750-06X) purchased from US Biological and were immobilised until sat-
uration (8000–9000 RU) on both flow cells, followed by ethanolamine blocking, as per guidelines provided in 
the GE Healthcare product manual. EPOR and βc proteins were biotinylated using EZ link sulfo-NHS biotin 
(ThermoFisher Scientific), with excess biotin removed by SEC (S200 10/300 increase column, GE Healthcare). 
Biotinylated EPOR was immobilised on active flow 2 cell and biotinylated βc on active flow cell 4, aiming at an 
Rmax of 100 for the level of immobilisation. All samples injected were buffer exchanged into the running buffer. 
Each surface was tested with a positive control (EPO for EPOR and IL-3 + IL-3 receptor α-subunit (IL-3Rα) 
for βc) before injection of samples of interest. All binding curves were double referenced, with blank flow cell 
and buffer subtractions in the analyses using the T200 Biacore Evaluation software. EPO was purchased from 
Genscript (Z02975-50) and IL-3 + IL-3Rα was prepared as described in58. Each experiment was conducted in 
duplicate, with N = 3 separate experiments.
Analytical ultracentrifugation (AUC). Sedimentation velocity AUC studies were carried out using a 
Beckman Coulter XL-I centrifuge equipped with UV/Vis scanning absorbance optics. Samples and reference 
buffer (10 mM HEPES, 500 mM NaCl pH 7.2) were loaded in double sector 12 mm cells with quartz windows 
and centrifuged at 20 °C and a rotor speed of 50,000 rpm (201,600 g) using either an An-60Ti 4-hole or An-50Ti 
8-hole rotor. Radial absorbance data were recorded during sedimentation at wavelengths chosen based on the 
absorbance of the protein samples. Buffer density (1.01944 g/mL) and viscosity (0.01057 P) were calculated using 
SEDNTERP59. The data were analysed and fitted to a continuous sedimentation coefficient model [c(s) model] 
using Sedfit60,61, with the partial specific volume calculated from SEDNTERP59 (0.7207 for βc, 0.7278 for EPOR, 
0.7418 for EPO, 0.7389 for IL-3, 0.7253 for IL-3Rα and an average of 0.73 for protein mixtures). EPO (3 μM), 
EPOR (1.5, 3, 6 μM) and βc (0.75, 1.5, 3 μM) were analysed for reference. Different combinations of samples 
(3 μM EPO + 3 μM EPOR, 3 μM EPO + 6 μM EPOR, 1.5 μM βc + 0.5 μM EPOR, 1.5 μM βc + 1.5 μM EPOR, 
1.5 μM βc + 6 μM EPOR, 5 μM EPO + 5 μM EPOR + 2.5 μM βc, 5 μM EPO + 5 μM EPOR + 5 μM βc and 5 μM 
EPO + 5 μM EPOR + 10 μM βc) were then analysed. Figures were generated using either SigmaPlot version 12.0 
(Systat Software, San Jose, CA) or Graphpad Prism version 7.0. EPO was purchased from Genscript (Z02975-50) 
for the AUC studies. Each set of experiments was performed once at the different concentrations.
Mouse studies. Female Csf2rb−/− mice31 were maintained on a C57BL/6 genetic background. Female 
age-matched wild type C57BL/6 mice (8–12 weeks) were used as controls. Phenylhydrazine was injected at day 
zero (D0) (60 mg/kg i.p.). Serial whole blood samples (20 μL) were collected prior to injection (D0), and again 
at D3, D5 and D7 for a complete blood count (CBC) as described62. At D7, a second injection of phenylhydazine 
(90 mg/kg i.p.) was delivered to mimic a delayed second anaemic stress event. Further CBCs were undertaken 
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at D10, D12 and D14 when the mice were sacrificed and spleen weight/body weight ratios measured. Red blood 
cell count and haematocrit data are presented as mean ± SD for N = 4 mice in each group. Spleen weights (g) for 
the same cohort are expressed as the average ± SD. A student’s test was used (in GraphPad) to determine if dif-
ferences between the two groups for each of the measured blood parameters or spleen weights was significant or 
not. All animal experiments were undertaken with the approval of the University of Queensland Animal Ethics 
Committee.
All experiments were performed in accordance with the relevant Institutional guidelines and regulations 
and, where required, approval was sought and granted by the relevant Institutional Biosafety Committees of St. 
Vincent’s Institute, University of Melbourne, Monash University and University of Queensland.
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